Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

被引:55
|
作者
Leib, Edward S. [1 ]
Saag, Kenneth G. [2 ]
Adachi, Jonathan D. [3 ]
Geusens, Piet P. [4 ,5 ]
Binkley, Neil [6 ]
McCloskey, Eugene V. [7 ]
Hans, Didier B. [8 ]
机构
[1] Univ Vermont, Coll Med, Burlington, VT 05401 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[4] Maastricht Univ Caphri, Dept Internal Med, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[5] Univ Hasselt, Biomed Res Ctr, Hasselt, Belgium
[6] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[7] Univ Sheffield, Sheffield, S Yorkshire, England
[8] Univ Lausanne Hosp, Dept Bone & Joint, Lausanne, Switzerland
基金
英国医学研究理事会;
关键词
Glucocorticoids; fracture risk; drug-induced osteoporosis; FRAX; BONE-MINERAL DENSITY; OBSTRUCTIVE PULMONARY-DISEASE; LOW-DOSE PREDNISONE; INHALED CORTICOSTEROIDS; ADDISONS-DISEASE; REPLACEMENT THERAPY; 21-HYDROXYLASE DEFICIENCY; INDUCED OSTEOPOROSIS; ORAL GLUCOCORTICOIDS; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.jocd.2011.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Given the significant impact the use of glucocorticoids can have on fracture risk independent of bone density, their use has been incorporated as one of the clinical risk factors for calculating the 10-year fracture risk in the World Health Organization's Fracture Risk Assessment Tool (FRAX (R)). Like the other clinical risk factors, the use of glucocorticoids is included as a dichotomous variable with use of steroids defined as past or present exposure of 3 months or more of use of a daily dose of 5 mg or more of prednisolone or equivalent. The purpose of this report is to give clinicians guidance on adjustments which should be made to the 10-year risk based on the dose, duration of use and mode of delivery of glucocorticoid preparations. A subcommittee of the International Society for Clinical Densitometry and International Osteoporosis Foundation joint Position Development Conference presented its findings to an expert panel and the following recommendations were selected. 1) There is a dose relationship between glucocorticoid use of greater than 3 months and fracture risk. The average dose exposure captured within FRAX (R) is likely to be a prednisone dose of 2.5-7.5 mg/day or its equivalent. Fracture probability is under-estimated when prednisone dose is greater than 7.5 mg/day and is over-estimated when the prednisone dose is less than 2.5 mg/day. 2) Frequent intermittent use of higher doses of glucocorticoids increases fracture risk. Because of the variability in dose and dosing schedule, quantification of this risk is not possible. 3) High dose inhaled glucocorticoids may be a risk factor for fracture. FRAX (R) may underestimate fracture probability in users of high dose inhaled glucocorticoids. 4) Appropriate glucocorticoid replacement in individuals with adrenal insufficiency has not been found to increase fracture risk. In such patients, use of glucocorticoids should not be included in FRAX (R) calculations.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [41] FRAX 10-Year Fracture Risk In Women With a Fracture Of The Distal Forearm: Agreement Between Assessments With and Without Bone Mineral Density and Influence Of Measurement Side In Individual Patients
    Egsmose, Emilie
    Birkvig, Mette
    Buhl, Thora
    Madsen, Ole Rintek
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S518 - S518
  • [42] THE PREVALENCE OF CLINICAL RISK FACTORS (RF) AND EVALUATION OF A 10-YEAR PROBABILITY OF OSTEOPOROTIC FRACTURES IN THE RUSSIAN POPULATION ON THE BASIS OF FRAX WITHOUT BMD
    Skripnikova, I. A.
    Gurev, A. V.
    Shalnova, S. A.
    Artamonova, G. V.
    Gatagonova, T. M.
    Grinstein, Y. I.
    Efanov, A. Y.
    Iljin, V. A.
    Kulakova, N. V.
    Nedogoda, S. V.
    Romanchuk, V.
    Boytsov, S. A.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S185 - S185
  • [43] CAN A 10 YEAR FRACTURE RISK SCORE (FRAX) BE USED TO AVOID DUAL ENERGY X-RAY ABSORPTIOMETRY (DEXA) SCANS IN PATIENTS WITH COELIAC DISEASE?
    Derbyshire, E.
    Dhar, A.
    GUT, 2012, 61 : A248 - A248
  • [44] FRAX 10-YEAR FRACTURE RISK IN RHEUMATOID ARTHRITIS - ASSESSMENTS WITH AND WITHOUT BONE MINERAL DENSITY MAY LEAD TO VERY DIFFERENT RESULTS IN THE INDIVIDUAL PATIENT
    Elde, K. D.
    Madsen, O. Rintek
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 217 - 217
  • [45] Fracture risk prediction using FRAX®: a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study
    J. Tamaki
    M. Iki
    E. Kadowaki
    Y. Sato
    E. Kajita
    S. Kagamimori
    Y. Kagawa
    H. Yoneshima
    Osteoporosis International, 2011, 22 : 3037 - 3045
  • [46] Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density
    Klop, Corinne
    de Vries, Frank
    Bijlsma, Johannes W. J.
    Leufkens, Hubert G. M.
    Welsing, Paco M. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (12) : 2095 - 2100
  • [47] Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos)
    George Ioannidis
    Shelley Pallan
    Alexandra Papaioannou
    Manisha Mulgund
    Lorena Rios
    Jinhui Ma
    Lehana Thabane
    Kenneth S. Davison
    Robert G. Josse
    Christopher S. Kovacs
    Nancy Kreiger
    Wojciech P. Olszynski
    Jerilynn C. Prior
    Tanveer Towheed
    Jonathan D. Adachi
    Archives of Osteoporosis, 2014, 9
  • [48] Glucocorticoids predict 10-year fragility fracture risk in a population-based ambulatory cohort of men and women: Canadian Multicentre Osteoporosis Study (CaMos)
    Ioannidis, George
    Pallan, Shelley
    Papaioannou, Alexandra
    Mulgund, Manisha
    Rios, Lorena
    Ma, Jinhui
    Thabane, Lehana
    Davison, Kenneth S.
    Josse, Robert G.
    Kovacs, Christopher S.
    Kreiger, Nancy
    Olszynski, Wojciech P.
    Prior, Jerilynn C.
    Towheed, Tanveer
    Adachi, Jonathan D.
    ARCHIVES OF OSTEOPOROSIS, 2014, 9 (01)
  • [49] CONFIRMED AND SEVERE SARCOPENIA BY EWGSOP2 PREDICT 10-YEAR FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD IN THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY: A META-ANALYSIS
    Harvey, N. C. W.
    Orwoll, E.
    Kwok, T.
    Karlsson, M. K.
    Rosengren, B. E.
    Ribom, E.
    Cauley, J.
    Cawthon, P. M.
    Ensrud, K.
    Liu, E.
    Cruz-Jentoft, A.
    Cooper, C.
    Kanis, J. A.
    Lorentzon, M.
    Ohlsson, C.
    Mellstrom, D.
    Johansson, H.
    Mccloskey, E.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S46 - S47
  • [50] UP TO HALF OF FIRST FRAGILITY FRACTURES (FF), AND A THIRD OF RECURRENT FF, OCCUR IN PATIENTS WITH LOW OR MODERATE ESTIMATED FRAX® 10-YEAR FRACTURE RISK: RESULTS FROM THE OPTIMUS INITIATIVE
    April, P. -M.
    Cabana, F.
    Beaulieu, M. -C.
    Beaulieu, M.
    Roux, S.
    Boire, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 294 - 294